» Authors » David A Braun

David A Braun

Explore the profile of David A Braun including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 76
Citations 2721
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Perales O, Jilaveanu L, Adeniran A, Su D, Hurwitz M, Braun D, et al.
Cancer Immunol Immunother . 2024 Aug; 73(10):192. PMID: 39105820
Purpose: Immune checkpoint inhibitors have revolutionized the treatment of renal cell carcinoma (RCC), but many patients do not respond to therapy and the majority develop resistant disease over time. Thus,...
12.
Bakouny Z, Braun D, Reznik E, Hakimi A
EBioMedicine . 2024 Jun; 105:105218. PMID: 38924842
No abstract available.
13.
Ali M, Eid M, Saliby R, Choi S, McKay R, Siva S, et al.
Am Soc Clin Oncol Educ Book . 2024 Jun; 44(3):e438658. PMID: 38875505
The management of renal cell carcinoma (RCC) has advanced significantly in the past two decades. Many promising functional imaging modalities such as radiolabeled tracer targeting carbonic anhydrase IX and prostate-specific...
14.
El Zarif T, Semaan K, Eid M, Seo J, Garinet S, Davidsohn M, et al.
Cell Rep . 2024 Jun; 43(6):114350. PMID: 38870013
Renal cell carcinoma with sarcomatoid differentiation (sRCC) is associated with poor survival and a heightened response to immune checkpoint inhibitors (ICIs). Two major barriers to improving outcomes for sRCC are...
15.
Saliby R, Labaki C, Jammihal T, Xie W, Sun M, Shah V, et al.
Cancer Cell . 2024 Apr; 42(5):732-735. PMID: 38579722
Saliby et al. show that a machine learning approach can accurately classify clear cell renal cell carcinoma (RCC) into distinct molecular subtypes using transcriptomic data. When applied to tumors biospecimens...
16.
Choueiri T, Donahue A, Braun D, Rini B, Powles T, Haanen J, et al.
Cancer Discov . 2024 Feb; 14(3):406-423. PMID: 38385846
Significance: Our findings provide novel insights into the different immunomodulatory mechanisms governing responses in patients treated with avelumab (PD-L1 inhibitor) + axitinib or sunitinib (both VEGF inhibitors), highlighting the contribution...
17.
Wang Y, Cho J, Kastrunes G, Buck A, Razimbaud C, Culhane A, et al.
iScience . 2024 Feb; 27(2):108879. PMID: 38327771
One of the major barriers that have restricted successful use of chimeric antigen receptor (CAR) T cells in the treatment of solid tumors is an unfavorable tumor microenvironment (TME). We...
18.
Saliby R, Saad E, Kashima S, Schoenfeld D, Braun D
Am Soc Clin Oncol Educ Book . 2024 Jan; 44(2):e430734. PMID: 38207251
Immune checkpoint inhibitors have significantly transformed the treatment paradigm for metastatic renal cell carcinoma (RCC), offering prolonged overall survival and achieving remarkable deep and durable responses. However, given the multiple...
19.
Denize T, Jegede O, Matar S, El Ahmar N, West D, Walton E, et al.
Clin Cancer Res . 2023 Dec; 30(4):803-813. PMID: 38060202
Purpose: Programmed cell death protein 1 (PD-1) expression on CD8+TIM-3-LAG-3- tumor-infiltrating cells predicts positive response to PD-1 blockade in metastatic clear-cell renal cell carcinoma (mccRCC). Because inhibition of PD-1 signaling...
20.
Schindler N, Braun D
Kidney Cancer . 2023 Nov; 7(1):81-91. PMID: 38014393
Immune checkpoint inhibitors (ICIs) have transformed the management of advanced renal cell carcinoma (RCC), but most patients still do not receive a long-term benefit from these therapies, and many experience...